SCHEMBL12873239

SCHEMBL12873239

CC1(C)C(=O)N(c2ccccc2-c2ccccc2)C(=O)N1Cc1ccccc1Oc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TNF P01375 1/20 0.43
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
TAS2R8 Q9NYW2 3/20 0.39
FAAH O00519 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.38
MGLL Q99685 1/20 0.37
BRD4 O60885 1/20 0.36
CYP19A1 P11511 1/20 0.36
RIPK1 Q13546 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
HTR7 P34969 1/20 0.35
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
PTGS2 P35354 1/20 0.35
ALDH1A1 P00352 1/20 0.35
NR1H2 P55055 2/20 0.34
HRH1 P35367 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12873244 0.90 HDAC1 (0.48) TNFHDAC1HDAC6TAS2R8FAAH
SCHEMBL12873223 0.87 HDAC1 (0.56) TNFHDAC1HDAC6TAS2R8FAAH
SCHEMBL12873215 0.87 HDAC1 (0.44) TNFHDAC1HDAC6TAS2R8FAAH
SCHEMBL8010597 0.86 HDAC1 (0.43) TNFHDAC1HDAC6TAS2R8FAAH
SCHEMBL8001609 0.86 HDAC1 (0.45) TNFHDAC1HDAC6TAS2R8FAAH
SCHEMBL8010587 0.86 HDAC1 (0.43) TNFHDAC1HDAC6TAS2R8FAAH
SCHEMBL8015549 0.85 HDAC1 (0.45) TNFHDAC1HDAC6TAS2R8FAAH
SCHEMBL8021533 0.85 HDAC1 (0.42) TNFHDAC1HDAC6TAS2R8FAAH
SCHEMBL8019464 0.84 TAS2R8 (0.44) HDAC1HDAC6TAS2R8FAAHPTGDR2
SCHEMBL8023307 0.84 TAS2R8 (0.47) TNFHDAC1HDAC6TAS2R8FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046185-A1 Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-02-24 US disclosed
US-20110046185-A1 Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046185-A1 Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof PGC, LIPC, CEL TNF 4192/4885HDAC1 1393/4885HDAC6 2952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.